The domain of novel cell cytometers, particularly flow cytometer, has attracted much attention within the global biopharmaceutical industry in recent years. This popularity can be attributed mainly to the need of these tools to address the rising prevalence of chronic disease conditions. Flow cytometers allow simultaneous characterization of cells from a mixed population, thereby helping